



ELSEVIER

Clinica Chimica Acta 281 (1999) 183–184




Author index

Volume 281 (1999)

- Abbondanza, A., see Battelli, M.G. **281**, 147
Al Chahin, G., see Nicolay, A. **281**, 29
Allers, P., see Ventura, F.V. **281**, 1
Amuro, Y., see Hada, T. **281**, 37
- Bargas, E., see Nicolay, A. **281**, 29
Battelli, M.G., Abbondanza, A., Musiani, S., Buonamici, L., Strocchi, P., Tazzari, P.L., Gramantieri, L., Stirpe, F., Determination of xanthine oxidase in human serum by a competitive enzyme-linked immunosorbent assay (ELISA) **281**, 147
Baumgrass, R., Daenzer, M., Felsenberg, D., Improved in vitro stability of serum osteocalcin by using a new commercially available antiproteolytic compound **281**, 47
Bellik, B., see Houzé, P. **281**, 77
Bertocchio, P., see Nicolay, A. **281**, 29
Boonstra, R., see Tinnikov, A.A. **281**, 159
Bouro, F., see Houzé, P. **281**, 77
Bousquet, B., see Houzé, P. **281**, 77
Brooks, S.S., see Junaid, M.A. **281**, 169
Buonamici, L., see Battelli, M.G. **281**, 147
- Clutter, W.E., see Landau-Levine, M. **281**, 177
Costa, C.G., see Ventura, F.V. **281**, 1
Coudoré, F., see Nicolay, A. **281**, 29
- Daenzer, M., see Baumgrass, R. **281**, 47
Duran, M., see Ventura, F.V. **281**, 1
- Extra, J.-M., see Houzé, P. **281**, 77
- Falkous, G., see Mantle, D. **281**, 101
Felsenberg, D., see Baumgrass, R. **281**, 47
Friedl, W., Mair, J., Thomas, S., Pichler, M., Puschendorf, B., Relationship between natriuretic peptides and hemodynamics in patients with heart failure at rest and after ergometric exercise **281**, 121
- Gaskin, K.J., see Hossein Nouri-Sorkhabi, M. **281**, 89
Gilvarg, C., see Stewart, J.D. **281**, 19
Gramantieri, L., see Battelli, M.G. **281**, 147
Gronowski, A.M., see Landau-Levine, M. **281**, 177
Gruca, M.A., see Hossein Nouri-Sorkhabi, M. **281**, 89
- Hada, T., Kondo, M., Yasukawa, K., Amuro, Y., Higashino, K., Discrimination of liver cirrhosis from chronic hepatitis by measuring the ratio of *Aleuria aurantia* lectin-reactive serum cholinesterase to immunoreactive protein **281**, 37
Hagino, H., see Meshitsuka, S. **281**, 163
Hiasa, Y., see Matsumoto, K. **281**, 57
Higashino, K., see Hada, T. **281**, 37
Horn, A., see Rhode, H. **281**, 127
Hossein Nouri-Sorkhabi, M., Gruca, M.A., Kuchel, P.W., Gaskin, K.J., Phospholipid changes in children with pancreatic sufficiency and insufficiency **281**, 89
Houzé, P., Bellik, B., Extra, J.-M., Bourou, F., Bousquet, B., Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer **281**, 77
- Ijlst, L., see Ventura, F.V. **281**, 1
Ikuta, Y., see Murawaki, Y. **281**, 109
Inoue, M., see Meshitsuka, S. **281**, 163
Jakobs, C., see Ventura, F.V. **281**, 1

- Junaid, M.A., Brooks, S.S., Wisniewski, K.E., Pullarkat, R.K., A novel assay for lysosomal pepstatin-insensitive proteinase and its application for the diagnosis of late-infantile neuronal ceroid lipofuscinosis **281**, 169
- Kawasaki, H., see Murawaki, Y. **281**, 109
- Kimura, E., see Matsumoto, K. **281**, 57
- Kofron, W.G., see Potter, J.L. **281**, 71
- Kondo, M., see Hada, T. **281**, 37
- Konishi, N., see Matsumoto, K. **281**, 57
- Kuchel, P.W., see Hossein Nouri-Sorkhabi, M. **281**, 89
- Landau-Levine, M., Way, B.A., Clutter, W.E., Scott, M.G., Gronowski, A.M., Antibody interference with the Abbott AxSym immunoassay for thyroid-stimulating hormone **281**, 177
- Lopatta, E., see Rhode, H. **281**, 127
- Mair, J., see Friedl, W. **281**, 121
- Mantle, D., Falkous, G., Peters, T.J., Preedy, V.R., Effect of ethanol and acetaldehyde on intracellular protease activities in human liver, brain and muscle tissues in vitro **281**, 101
- Matsumoto, K., Konishi, N., Hiasa, Y., Kimura, E., Takahashi, Y., Shinohara, K., Samori, T., A highly sensitive enzyme-linked immunoassay for serum free prostate specific antigen (f-PSA) **281**, 57
- Meshitsuka, S., Yamazaki, E., Inoue, M., Hagino, H., Teshima, R., Yamamoto, K., Nuclear magnetic resonance studies of synovial fluids from patients with rheumatoid arthritis and osteoarthritis **281**, 163
- Murawaki, Y., Ikuta, Y., Kawasaki, H., Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1 **281**, 109
- Musiani, S., see Battelli, M.G. **281**, 147
- Nicolay, A., Bertocchio, P., Bargas, E., Coudoré, F., Al Chahin, G., Reynier, J.-P., Hyperkalemia risks in hemodialysed patients consuming fluoride-rich water **281**, 29
- Pascual, C., see Rhode, H. **281**, 127
- Peters, T.J., see Mantle, D. **281**, 101
- Pichler, M., see Friedl, W. **281**, 121
- Potter, J.L., Timmons, G.D., Kofron, W.G., Radiocontrast interference in screening tests for genetic-metabolic diseases **281**, 71
- Preedy, V.R., see Mantle, D. **281**, 101
- Pullarkat, R.K., see Junaid, M.A. **281**, 169
- Puschendorf, B., see Friedl, W. **281**, 121
- Reinhart, K., see Rhode, H. **281**, 127
- Reynier, J.-P., see Nicolay, A. **281**, 29
- Rhode, H., Lopatta, E., Schulze, M., Pascual, C., Schulze, H.-P., Schubert, K., Schubert, H., Reinhart, K., Horn, A., Glycosylphosphatidylinositol-specific phospholipase D in blood serum: Is the liver the only source of the enzyme? **281**, 127
- Ruiter, J., see Ventura, F.V. **281**, 1
- Samori, T., see Matsumoto, K. **281**, 57
- Schubert, H., see Rhode, H. **281**, 127
- Schubert, K., see Rhode, H. **281**, 127
- Schulze, H.-P., see Rhode, H. **281**, 127
- Schulze, M., see Rhode, H. **281**, 127
- Scott, M.G., see Landau-Levine, M. **281**, 177
- Shinohara, K., see Matsumoto, K. **281**, 57
- Stewart, J.D., Gilvarg, C., Determination of the activity of carboxypeptidase A in the blood of healthy human adults **281**, 19
- Stirpe, F., see Battelli, M.G. **281**, 147
- Strocchi, P., see Battelli, M.G. **281**, 147
- Struys, E.A., see Ventura, F.V. **281**, 1
- Takahashi, Y., see Matsumoto, K. **281**, 57
- Tavares de Almeida, I., see Ventura, F.V. **281**, 1
- Tazzari, P.L., see Battelli, M.G. **281**, 147
- Teshima, R., see Meshitsuka, S. **281**, 163
- Thomas, S., see Friedl, W. **281**, 121
- Timmons, G.D., see Potter, J.L. **281**, 71
- Tinnikov, A.A., Boonstra, R., Colorimetric microdetermination of free fatty acids in plasma using microplate readers **281**, 159
- Ventura, F.V., Costa, C.G., Struys, E.A., Ruiter, J., Allers, P., Ijlst, L., Tavares de Almeida, I., Duran, M., Jakobs, C., Wanders, R.J.A., Quantitative acylcarnitine profiling in fibroblasts using [U-¹³C] palmitic acid: an improved tool for the diagnosis of fatty acid oxidation defects **281**, 1
- Wanders, R.J.A., see Ventura, F.V. **281**, 1
- Way, B.A., see Landau-Levine, M. **281**, 177
- Wisniewski, K.E., see Junaid, M.A. **281**, 169
- Yamamoto, K., see Meshitsuka, S. **281**, 163
- Yamazaki, E., see Meshitsuka, S. **281**, 163
- Yasukawa, K., see Hada, T. **281**, 37



ELSEVIER

Clinica Chimica Acta 281 (1999) 185–187



Subject index

Volume 281 (1999)

- Acetaldehyde**; Ethanol; Proteases; Protein degradation; Liver; Muscle; Brain **281**, 101
- Basal carboxypeptidase A serum concentrations**; Sensitive carboxypeptidase A assay; Pancreatitis detection; Serum enzyme **281**, 19
- Batten disease**; Neuronal ceroid lipofuscinoses; Lysosome; Proteinase; Pepstatin-insensitive; Cultured cells **281**, 169
- Bone Gla Protein**; Osteocalcin; Peptide fragments **281**, 47
- Bone metastases**; Carboxyterminal telopeptide collagen I; Breast cancer **281**, 77
- Brain**; Ethanol; Acetaldehyde; Proteases; Protein degradation; Liver; Muscle **281**, 101
- Breast cancer**; Carboxyterminal telopeptide collagen I; Bone metastases **281**, 77
- Capillary blood**; Glycosylphosphatidylinositol specific phospholipase D; GPI; Sepsis; Inflammation; Phospholipase inhibitor **281**, 127
- Carboxyterminal telopeptide collagen I**; Breast cancer; Bone metastases **281**, 77
- Chronic liver disease**; Lectin; Sugar chain; ELISA **281**, 37
- Congestive heart failure**; Natriuretic peptides; Right heart catheterization; Ergometry **281**, 121
- Cultured cells**; Neuronal ceroid lipofuscinoses; Batten disease; Lysosome; Proteinase; Pepstatin-insensitive **281**, 169
- Cystic fibrosis**; Phospholipids; Pancreatic sufficiency; Pancreatic insufficiency; Phospholipase A₂; ³¹P-NMR **281**, 89
- Diagnosis of mitochondrial fatty acid β -oxidation disorders**; Inborn errors of metabolism; In vitro acylcarnitines **281**, 1
- ELISA**; Human milk xanthine oxidase; Human serum xanthine oxidase; Rabbit polyclonal antibodies **281**, 147
- ELISA**; Lectin; Sugar chain; Chronic liver disease **281**, 37
- Enzyme-linked immunoassay**; Monoclonal antibodies; Free prostate specific antigen; Tumor marker **281**, 57
- Ergometry**; Natriuretic peptides; Congestive heart failure; Right heart catheterization **281**, 121
- Ethanol**; Acetaldehyde; Proteases; Protein degradation; Liver; Muscle; Brain **281**, 101
- Fluoride**; Hemodialysis; Kalemia; Plasma fluoride level; Vichy St-Yorre water **281**, 29
- Free fatty acids**; Plasma microplate reader; Rabbits **281**, 159
- Free prostate specific antigen**; Monoclonal antibodies; Enzyme-linked immunoassay; Tumor marker **281**, 57

- GPI**; Glycosylphosphatidylinositol specific phospholipase D; Sepsis; Inflammation; Phospholipase inhibitor; Capillary blood **281**, 127
- Genetic-metabolic screening**; Radiocontrast interference **281**, 71
- Glycosylphosphatidylinositol specific phospholipase D**; GPI; Sepsis; Inflammation; Phospholipase inhibitor; Capillary blood **281**, 127
- Hemodialysis**; Fluoride; Kalemia; Plasma fluoride level; Vichy St-Yorre water **281**, 29
- Heterophilic antibodies**; Immunoassay; Thyroid-stimulating hormone (TSH) **281**, 177
- Human milk xanthine oxidase**; Human serum xanthine oxidase; Rabbit polyclonal antibodies; ELISA **281**, 147
- Human serum xanthine oxidase**; Human milk xanthine oxidase; Rabbit polyclonal antibodies; ELISA **281**, 147
- Immunoassay**; Heterophilic antibodies; Thyroid-stimulating hormone (TSH) **281**, 177
- In vitro acylcarnitines**; Diagnosis of mitochondrial fatty acid β -oxidation disorders; Inborn errors of metabolism **281**, 1
- Inborn errors of metabolism**; Diagnosis of mitochondrial fatty acid β -oxidation disorders; In vitro acylcarnitines **281**, 1
- Inflammation**; Glycosylphosphatidylinositol specific phospholipase D; GPI; Sepsis; Phospholipase inhibitor; Capillary blood **281**, 127
- Kalemia**; Fluoride; Hemodialysis; Plasma fluoride level; Vichy St-Yorre water **281**, 29
- Lactate**; Synovial fluid; Nuclear magnetic resonance; Rheumatoid arthritis; Osteoarthritis **281**, 163
- Lectin**; Sugar chain; Chronic liver disease; ELISA **281**, 37
- Liver disease**; Metalloproteinase inhibitor; TIMP-2; TIMP-1 **281**, 109
- Liver**; Ethanol; Acetaldehyde; Proteases; Protein degradation; Muscle; Brain **281**, 101
- Lysosome**; Neuronal ceroid lipofuscinoses; Batten disease; Proteinase; Pepstatin-insensitive; Cultured cells **281**, 169
- Metalloproteinase inhibitor**; TIMP-2; TIMP-1; Liver disease **281**, 109
- Monoclonal antibodies**; Free prostate specific antigen; Enzyme-linked immunoassay; Tumor marker **281**, 57
- Muscle**; Ethanol; Acetaldehyde; Proteases; Protein degradation; Liver; Brain **281**, 101
- Natriuretic peptides**; Congestive heart failure; Right heart catheterization; Ergometry **281**, 121
- Neuronal ceroid lipofuscinoses**; Batten disease; Lysosome; Proteinase; Pepstatin-insensitive; Cultured cells **281**, 169
- Nuclear magnetic resonance**; Synovial fluid; Rheumatoid arthritis; Osteoarthritis; Lactate **281**, 163
- Osteoarthritis**; Synovial fluid; Nuclear magnetic resonance; Rheumatoid arthritis; Lactate **281**, 163
- Osteocalcin**; Bone Gla Protein; Peptide fragments **281**, 47
- Pancreatic insufficiency**; Phospholipids; Pancreatic sufficiency; Cystic fibrosis; Phospholipase A₂; ³¹P-NMR **281**, 89
- Pancreatic sufficiency**; Phospholipids; Pancreatic insufficiency; Cystic fibrosis; Phospholipase A₂; ³¹P-NMR **281**, 89
- Pancreatitis detection**; Basal carboxypeptidase A serum concentrations; Sensitive carboxypeptidase A assay; Serum enzyme **281**, 19
- Pepstatin-insensitive**; Neuronal ceroid lipofuscinoses; Batten disease; Lysosome; Proteinase; Cultured cells **281**, 169
- Peptide fragments**; Osteocalcin; Bone Gla Protein **281**, 47
- Phospholipase A₂**; Phospholipids; Pancreatic sufficiency; Pancreatic insufficiency; Cystic fibrosis; ³¹P-NMR **281**, 89

- Phospholipase inhibitor;** Glycosylphosphatidylinositol specific phospholipase D; GPI; Sepsis; Inflammation; Capillary blood **281, 127**
- Phospholipids;** Pancreatic sufficiency; Pancreatic insufficiency; Cystic fibrosis; Phospholipase A₂; ³¹P-NMR **281, 89**
- Plasma fluoride level;** Fluoride; Hemodialysis; Kalemia; Vichy St-Yorre water **281, 29**
- Plasma microplate reader;** Free fatty acids; Rabbits **281, 159**
- ³¹P-NMR;** Phospholipids; Pancreatic sufficiency; Pancreatic insufficiency; Cystic fibrosis; Phospholipase A₂ **281, 89**
- Proteases;** Ethanol; Acetaldehyde; Protein degradation; Liver; Muscle; Brain **281, 101**
- Protein degradation;** Ethanol; Acetaldehyde; Proteases; Liver; Muscle; Brain **281, 101**
- Proteinase;** Neuronal ceroid lipofuscinoses; Batten disease; Lysosome; Pepstatin-insensitive; Cultured cells **281, 169**
- Rabbit polyclonal antibodies;** Human milk xanthine oxidase; Human serum xanthine oxidase; ELISA **281, 147**
- Rabbits;** Free fatty acids; Plasma microplate reader **281, 159**
- Radiocontrast interference;** Genetic-metabolic screening **281, 71**
- Rheumatoid arthritis;** Synovial fluid; Nuclear magnetic resonance; Osteoarthritis; Lactate **281, 163**
- Right heart catheterization;** Natriuretic peptides; Congestive heart failure; Ergometry **281, 121**
- Sensitive carboxypeptidase A assay;** Basal carboxypeptidase A serum concentrations; Pancreatitis detection; Serum enzyme **281, 19**
- Sepsis;** Glycosylphosphatidylinositol specific phospholipase D; GPI; Inflammation; Phospholipase inhibitor; Capillary blood **281, 127**
- Serum enzyme;** Basal carboxypeptidase A serum concentrations; Sensitive carboxypeptidase A assay; Pancreatitis detection **281, 19**
- Sugar chain;** Lectin; Chronic liver disease; ELISA **281, 37**
- Synovial fluid;** Nuclear magnetic resonance; Rheumatoid arthritis; Osteoarthritis; Lactate **281, 163**
- TIMP-1;** Metalloproteinase inhibitor; TIMP-2; Liver disease **281, 109**
- TIMP-2;** Metalloproteinase inhibitor; TIMP-1; Liver disease **281, 109**
- Thyroid-stimulating hormone (TSH);** Heterophilic antibodies; Immunoassay **281, 177**
- Tumor marker;** Monoclonal antibodies; Free prostate specific antigen; Enzyme-linked immunoassay **281, 57**
- Vichy St-Yorre water;** Fluoride; Hemodialysis; Kalemia; Plasma fluoride level **281, 29**